Biotech Values

[dia76ca]

Dew, I think Migenix has a lot more in its pipline than is reflected in a 40 cent share price. But in regard to celgosivir...you describe its non-responder results as "not bad' and a NZ virologist describes them as "encouraging". It is no magic bullet...but I don't think there is a magic bullet. It looks like the SOC will be a combination regime of possibly 5 or 6 compounds(as with HIV?). As first(and only?) in class I simply think it will be seen as deserving more research by some BP...and I would rather see a number of companies looking at the data from the non-responder and upcoming niave interim report than Schering alone. I think shareholders stand to gain more out an auction than the former agreement with Schering. It is a very competitive and huge market ($9-10B by 2010)and every little edge could be very important...and some BP may have something that celgosivir is even more synergistic with than Scherings compounds. Only time will tell.